secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001274737-23-000004
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen appoints Tina S. Nova, Ph.D. as Executive Chair, effective Jan 19, 2023
------------------------------------------------------------------------------

- Dr. Nova replaces Brian Birk, who remains on the Board.
- Nova is President of Veracyte's U.S. CLIA business; former CEO of Decipher Biosciences.
- Nova co-founded Genoptix (sold to Novartis for $470M) and held leadership at Illumina.
- Company says her experience will help expand its position in autoimmune testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/0001274737-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/exdx-20230123.htm
  HTML page:      https://secwatch.observer/filing/0001274737-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer